<DOC>
	<DOCNO>NCT00129896</DOCNO>
	<brief_summary>This open-label study ass efficacy tolerability combination Myocet®/Taxotere®/Herceptin® primary treatment HER2 positive breast cancer patient . HER2 status confirm centrally fluorescence situ hybridization ( FISH ) . Phase I : Initial dos : Myocet : 50-60 mg/m² day 1 every 3 week ; Taxotere 60-75 mg/m² day 1 every 3 week ; Herceptin ( 4 ) 2 mg/kg weekly . Sample size depend number patient recruit dose escalation . Three patient must recruit dose level . If one three experience dose-limiting toxicity ( DLT ) , 3 patient must recruit dose level . Considering 4 dose level test , estimate number patient 9 24 . Patients receive recommend dose ( RD ) incorporate phase II study . Phase II : The average pathological complete response rate report trial around 11 % . The investigator expect achieve increase 14 % rate ; , expect pathological response rate 25 % . With a= 0.05 β=0.2 , 18 patient initially need . If least 3 pathological complete response achieve , recruitment continue 53 patient . At least 10 pathological complete response need probe hypothesis . Considering 10 % post-randomization drop-out rate , total 59 patient must recruit trial .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin HER2 Positive Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Written inform consent . Breast cancer stage II IIIA histological diagnosis truecut . Breast cancer tumours overexpressing HER2neu , centrally confirm FISH . No evidence metastasis : bilateral mammography , thorax xray , compute tomography ( CT ) scan abdominal echography bone scintigraphy . Estrogen progesterone hormone receptor status , determine study registration . Age &gt; = 18 year old . Performance status ( Karnofsky index ) &gt; = 80 . Adequate cardiac function LVEF previous 14 day . Hematology : neutrophil &gt; = 2.0 x10^9/l ; platelet &gt; = 100 x10^9/l ; hemoglobin &gt; = 10 g/dl . Adequate hepatic function : total bilirubin &lt; = 1x upper normal limit ( UNL ) ; SGOT SGPT &lt; = 2.5xUNL ; alkaline phosphatase &lt; = 2.5xUNL . Adequate renal function : creatinine &lt; = 1xUNL ; creatinine clearance &gt; = 60 ml/min . Patients able comply study treatment followup . Negative pregnancy test previous 14 day . Adequate contraceptive method study 3 month definitive surgery . HER2neu negative tumour . Prior systemic therapy breast cancer . Prior treatment anthracyclines taxanes ( paclitaxel , docetaxel ) previous malignancy . Prior radiotherapy breast cancer . Bilateral invasive breast cancer . Pregnant lactating woman . Previous grade &gt; = 2 motor sensorial neurotoxicity ( National Cancer Institute Common Toxicity Criteria [ NCI CTC ] ) . Other serious comorbidities : congestive heart failure unstable angina ; prior history myocardial infarction previous year ; uncontrolled hypertension ( HT ) ; high risk arrhythmias ; history significant neurological psychiatric disorder ; uncontrolled active infection ; active peptic ulcer ; unstable diabetes mellitus ; dyspnea rest ; chronic therapy oxygen . Previous current history neoplasms different breast cancer , except skin carcinoma , cervical situ carcinoma , tumor curatively treat without recurrence last 10 year ; ductal situ carcinoma breast ; lobular situ carcinoma . Chronic treatment corticosteroid . Contraindications administration corticosteroid , anthracyclines , docetaxel , trastuzumab egg derivates . Concomitant treatment therapy cancer . Males .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Her2neu positive breast cancer .</keyword>
	<keyword>Neoadjuvant treatment .</keyword>
</DOC>